Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-target Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine Maintenance Therapy Treating Oligometastatic Nasopharyngeal Carcinoma: a Single-arm, Multicenter, Prospective, Open-label Phase II Clinical Trial

NCT05290194 is registered in ClinicalTrials.gov with Fifth Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT05290194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05290194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-target Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine Maintenance Therapy Treating Oligometastatic Nasopharyngeal Carcinoma: a Single-arm, Multicenter, Prospective, Open-label Phase II Clinical Trial
Lead sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 2
Overall status
Withdrawn
Start date
March 28, 2022
Completion date
March 31, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

capecitabine, nasopharyngeal carcinoma, pd-1 inhibitor, radiotherapy